Pharmsville Co., Ltd.

Pharmsville Co., Ltd.

KKRX:318010
3,255.00
KRW
-100.00
(-2.98%)
390.79EPS
8.51P/E
25.43BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3,299.2
4,511.91
5,001.92
4,972.15
3,329.42
2,734.53
2,165.87
1,648.01
1,449.48
Basic EPS, GAAP
805
1,093
367
637
518
423
205
374
386.8
Free Cash Flow per Basic Share
645.1
-177.89
-441.64
1,012.55
645.04
557.05
-58.49
236.07
173.25
Dividend per Share
39.92
37.96
201.29
99.96
100.04
100.29
100.36
100.06
- -
Book Value per Share
4,272.53
6,987.24
7,093.03
7,544.87
7,973.3
8,247.04
8,348.98
8,596.02
8,612.29
Tangible Book Value per Share
4,233.75
6,928.5
7,036.18
7,488.3
7,916.28
8,196.48
8,290.64
8,532.07
8,528.24
Basic Weighted Avg Shares
6
7
8
8
8
8
8
8
8
Sales/Revenue/Turnover
19,833
29,952
39,409
39,028
26,113
21,395
16,725
12,728
11,202
Operating Margin (%)
28.24
24.03
10.93
15.78
15.56
7.68
-1.54
-5.29
-6.14
Depreciation Expense
190
304
215
216
671
676
675
641
551
Net Income, GAAP
4,839
7,256
2,891
5,000
4,063
3,310
1,583
2,889
2,989
Effective Tax Rate (%)
23.36
21.4
16.64
18.95
21.73
16.62
13.48
19.17
25.73
Profit Margin (%)
24.4
24.22
7.34
12.81
15.56
15.47
9.47
22.69
26.69
Working Capital
13,312
38,524
40,106
41,442
40,866
38,177
39,069
39,580
36,110
LT Debt
1,340
4,421
8,000
5,347
3,643
3
16
12
9
Total Equity
27,030
55,507
55,762
59,304
62,667
64,016
64,624
66,547
66,691
Return on Invested Capital (%)
- -
12.2
5.68
7.53
4.58
1.99
-0.34
-0.83
-0.77
Return on Capital (%)
- -
16.12
4.79
7.7
6.09
5.05
2.48
4.38
4.48
Return on Common Equity (%)
- -
17.63
5.21
8.71
6.67
5.23
2.47
4.41
4.53

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
4
5
LT Borrowings
- -
- -
- -
LT Finance Leases
12
12
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
26,546
26,314
25,426

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
41,487
41,677
37,707
Cash, Cash Equivalents & STI
39,105
39,525
35,771
Accounts Receivable, Net
802
613
577
Inventories
1,358
1,285
1,210
Total Current Liabilities
1,907
1,507
1,597
Payables & Accruals
- -
- -
- -
ST Debt
5
4
5
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
3.62%
2.98%
Free Cash Flow
- -
-198.53%
-503.67%
Net Income, GAAP
- -
13.19%
82.47%
Sales/Revenue/Turnover
- -
-19.57%
-23.9%
Total Cash Common Dividend
- -
- -
-0.28%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,792
4,089
4,249
3,595
16,725
2025
3,338
3,058
3,370
2,963
12,728
2026
2,486
2,383
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
107
-57
32
122.83
205
2025
143
60
63.88
106.66
374
2026
155.92
60.35
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
100.36
2025
- -
- -
- -
- -
100.06
2026
- -
- -
- -
- -
- -

Company Description

CEO
Byeong-Wuk Lee
Full Time Employees
23
Sector
Retail trade
Industry
Drugstore chains
Address
Seoul South Korea
IPO Date
Oct 22, 2019
Business
Pharmsville Co., Ltd. is a South Korea-based healthcare and biotechnology company primarily engaged in the research, development, manufacturing, and distribution of health functional foods, dietary supplements, inner beauty products, and functional cosmetics. Founded in 2000 and headquartered in Seoul, South Korea, the company operates across the nutraceutical, preventive healthcare, and cosmeceutical sectors, serving domestic and international consumer markets. Pharmsville commercializes proprietary formulations through a diverse brand portfolio that includes Applephenon, Devil's Diet, Vitamin Village, and Lavieng. The company's core product and service offerings comprise weight management and metabolic health solutions, including apple polyphenol extracts, Garcinia cambogia formulas, and dietary fiber supplements; cognitive and neurological health formulations, featuring phosphatidylserine brain health and memory support complexes; ocular wellness products, consisting of lutein, zeaxanthin, and astaxanthin eye health formulas; inner beauty and anti-aging treatments, including low-molecular fish collagen peptides, oral hyaluronic acid, and glutathione supplements; gastrointestinal and immune health solutions, encompassing multi-strain probiotics, prebiotics, and zinc formulations; joint and bone health products, featuring methylsulfonylmethane, calcium, and vitamin D complexes; general wellness and vitality products, including multivitamin complexes, milk thistle liver support formulas, and fermented red ginseng extracts; functional skincare and cosmeceutical lines; and algorithm-driven personalized dietary supplement consultation and subscription services. The company distributes its products through omnichannel networks, including television home shopping broadcasts, direct-to-consumer online shopping malls, duty-free retailers, pharmacies, and major offline retail chains, with expanding export footprints across Greater China, Southeast Asia, North America, and Europe. In recent operational and strategic developments, Pharmsville has diversified its business model by expanding its algorithm-powered personalized functional food service, providing individualized nutritional diagnostic assessments and custom-portioned packaging. The company has also expanded its research infrastructure through its Magok R&D Center in Seoul, advancing clinical validation for novel proprietary bio-ingredients and functional food raw materials. In addition, Pharmsville has accelerated international expansion via direct cross-border e-commerce storefronts on major Asian digital commerce platforms and broadened its commercial scope into the pet healthcare segment with the launch of specialized functional supplements for companion animals.